Alleviation of methyl isocyanate−induced airway obstruction and mortality by tissue plasminogen activator

Methyl isocyanate (MIC, “Bhopal agent”) is a highly reactive, toxic industrial chemical. Inhalation of high levels (500–1000 ppm) of MIC vapor is almost uniformly fatal. No therapeutic interventions other than supportive care have been described that can delay the onset of illness or death due to MI...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the New York Academy of Sciences 2020-11, Vol.1479 (1), p.134-147
Hauptverfasser: Nick, Heidi J., Rioux, Jacqueline S., Veress, Livia A., Bratcher, Preston E., Bloomquist, Leslie A., Anantharam, Poojya, Croutch, Claire R., Tuttle, Richard S., Peters, Eric, Sosna, William, White, Carl W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 147
container_issue 1
container_start_page 134
container_title Annals of the New York Academy of Sciences
container_volume 1479
creator Nick, Heidi J.
Rioux, Jacqueline S.
Veress, Livia A.
Bratcher, Preston E.
Bloomquist, Leslie A.
Anantharam, Poojya
Croutch, Claire R.
Tuttle, Richard S.
Peters, Eric
Sosna, William
White, Carl W.
description Methyl isocyanate (MIC, “Bhopal agent”) is a highly reactive, toxic industrial chemical. Inhalation of high levels (500–1000 ppm) of MIC vapor is almost uniformly fatal. No therapeutic interventions other than supportive care have been described that can delay the onset of illness or death due to MIC. Recently, we found that inhalation of MIC caused the appearance of activated tissue factor in circulation with subsequent activation of the coagulation cascade. Herein, we report that MIC exposure (500 ppm for 30 min, nose‐only) caused deposition of fibrin‐rich casts in the conducting airways resulting in respiratory failure and death within 24 h in a rat model (LC90−100). We thus investigated the effect of airway delivery of the fibrinolytic agent tissue plasminogen activator (tPA) on mortality and morbidity in this model. Intratracheal administration of tPA was initiated 11 h post MIC exposure and repeated every 4 h for the duration of the study. Treatment with tPA afforded nearly 60% survival at 24 h post MIC exposure and was associated with decreased airway fibrin casts, stabilization of hypoxemia and respiratory distress, and improved acidosis. This work supports the potential of airway‐delivered tPA therapy as a useful countermeasure in stabilizing victims of high‐level MIC exposure. Our study demonstrates that airway‐delivered tPA provided partial protection against mortality, and substantially decreased airway obstruction in an acutely lethal model of MIC inhalation exposure. This approach could be useful for airway clearance in acute therapy of MIC inhalation−induced respiratory distress. Furthermore, a similar therapeutic regimen may potentially alleviate lung injuries due to other isocyanates or diisocyanates, thereby expanding its clinical importance.
doi_str_mv 10.1111/nyas.14344
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7529679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2462580962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4484-ce71ba65a2b389e83bbb35d87c6c831b709e6ee283e5cecee696bde7ef568a103</originalsourceid><addsrcrecordid>eNp9kb1uFDEQxy1ERI5AwwMgS3RIG_y1_miQThEBpIgUQEFl2d65xGF3fdjei_YNUvOIPAmbXIigYZop5je_GemP0AtKjulSb8bZlWMquBCP0IoqYRopOXuMVoQo1WjD-CF6WsoVIZRpoZ6gQ84Y58SYFfq-7nvYRVdjGnHa4AHq5dzjWFKY3egq_Lr5GcduCtBhF_O1m3HypeYp3G24scNDytX1sc7Yz7jGUibA296VIY7pAhZmQXeupvwMHWxcX-D5fT9CX0_ffTn50Jydv_94sj5rghBaNAEU9U62jnmuDWjuvedtp1WQQXPqFTEgAZjm0AYIANJI34GCTSu1o4Qfobd773byA3QBxppdb7c5Di7PNrlo_52M8dJepJ1VLTNSmUXw6l6Q048JSrVXacrj8rNlQrJWEyPZQr3eUyGnUjJsHi5QYm-DsbfB2LtgFvjl3z89oH-SWAC6B65jD_N_VPbTt_XnvfQ3sUieuA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2462580962</pqid></control><display><type>article</type><title>Alleviation of methyl isocyanate−induced airway obstruction and mortality by tissue plasminogen activator</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Nick, Heidi J. ; Rioux, Jacqueline S. ; Veress, Livia A. ; Bratcher, Preston E. ; Bloomquist, Leslie A. ; Anantharam, Poojya ; Croutch, Claire R. ; Tuttle, Richard S. ; Peters, Eric ; Sosna, William ; White, Carl W.</creator><creatorcontrib>Nick, Heidi J. ; Rioux, Jacqueline S. ; Veress, Livia A. ; Bratcher, Preston E. ; Bloomquist, Leslie A. ; Anantharam, Poojya ; Croutch, Claire R. ; Tuttle, Richard S. ; Peters, Eric ; Sosna, William ; White, Carl W.</creatorcontrib><description>Methyl isocyanate (MIC, “Bhopal agent”) is a highly reactive, toxic industrial chemical. Inhalation of high levels (500–1000 ppm) of MIC vapor is almost uniformly fatal. No therapeutic interventions other than supportive care have been described that can delay the onset of illness or death due to MIC. Recently, we found that inhalation of MIC caused the appearance of activated tissue factor in circulation with subsequent activation of the coagulation cascade. Herein, we report that MIC exposure (500 ppm for 30 min, nose‐only) caused deposition of fibrin‐rich casts in the conducting airways resulting in respiratory failure and death within 24 h in a rat model (LC90−100). We thus investigated the effect of airway delivery of the fibrinolytic agent tissue plasminogen activator (tPA) on mortality and morbidity in this model. Intratracheal administration of tPA was initiated 11 h post MIC exposure and repeated every 4 h for the duration of the study. Treatment with tPA afforded nearly 60% survival at 24 h post MIC exposure and was associated with decreased airway fibrin casts, stabilization of hypoxemia and respiratory distress, and improved acidosis. This work supports the potential of airway‐delivered tPA therapy as a useful countermeasure in stabilizing victims of high‐level MIC exposure. Our study demonstrates that airway‐delivered tPA provided partial protection against mortality, and substantially decreased airway obstruction in an acutely lethal model of MIC inhalation exposure. This approach could be useful for airway clearance in acute therapy of MIC inhalation−induced respiratory distress. Furthermore, a similar therapeutic regimen may potentially alleviate lung injuries due to other isocyanates or diisocyanates, thereby expanding its clinical importance.</description><identifier>ISSN: 0077-8923</identifier><identifier>EISSN: 1749-6632</identifier><identifier>DOI: 10.1111/nyas.14344</identifier><identifier>PMID: 32233099</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acidosis ; Airway management ; airway obstruction ; Airway Obstruction - chemically induced ; Airway Obstruction - drug therapy ; Airway Obstruction - physiopathology ; Animals ; Bhopal agent ; Coagulation ; Disease Models, Animal ; Exposure ; Fibrin ; Hypoxemia ; Inhalation ; Isocyanates ; Isocyanates - toxicity ; Male ; Methyl isocyanate ; methyl isocyanate (MIC) ; Morbidity ; Mortality ; Rats ; Rats, Sprague-Dawley ; Respiration ; Respiratory failure ; Respiratory tract ; t-Plasminogen activator ; Therapeutic applications ; Tissue factor ; tissue plasminogen activator (tPA) ; Tissue Plasminogen Activator - pharmacology ; Trachea</subject><ispartof>Annals of the New York Academy of Sciences, 2020-11, Vol.1479 (1), p.134-147</ispartof><rights>2020 New York Academy of Sciences.</rights><rights>2020 The New York Academy of Sciences</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4484-ce71ba65a2b389e83bbb35d87c6c831b709e6ee283e5cecee696bde7ef568a103</citedby><cites>FETCH-LOGICAL-c4484-ce71ba65a2b389e83bbb35d87c6c831b709e6ee283e5cecee696bde7ef568a103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fnyas.14344$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fnyas.14344$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32233099$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nick, Heidi J.</creatorcontrib><creatorcontrib>Rioux, Jacqueline S.</creatorcontrib><creatorcontrib>Veress, Livia A.</creatorcontrib><creatorcontrib>Bratcher, Preston E.</creatorcontrib><creatorcontrib>Bloomquist, Leslie A.</creatorcontrib><creatorcontrib>Anantharam, Poojya</creatorcontrib><creatorcontrib>Croutch, Claire R.</creatorcontrib><creatorcontrib>Tuttle, Richard S.</creatorcontrib><creatorcontrib>Peters, Eric</creatorcontrib><creatorcontrib>Sosna, William</creatorcontrib><creatorcontrib>White, Carl W.</creatorcontrib><title>Alleviation of methyl isocyanate−induced airway obstruction and mortality by tissue plasminogen activator</title><title>Annals of the New York Academy of Sciences</title><addtitle>Ann N Y Acad Sci</addtitle><description>Methyl isocyanate (MIC, “Bhopal agent”) is a highly reactive, toxic industrial chemical. Inhalation of high levels (500–1000 ppm) of MIC vapor is almost uniformly fatal. No therapeutic interventions other than supportive care have been described that can delay the onset of illness or death due to MIC. Recently, we found that inhalation of MIC caused the appearance of activated tissue factor in circulation with subsequent activation of the coagulation cascade. Herein, we report that MIC exposure (500 ppm for 30 min, nose‐only) caused deposition of fibrin‐rich casts in the conducting airways resulting in respiratory failure and death within 24 h in a rat model (LC90−100). We thus investigated the effect of airway delivery of the fibrinolytic agent tissue plasminogen activator (tPA) on mortality and morbidity in this model. Intratracheal administration of tPA was initiated 11 h post MIC exposure and repeated every 4 h for the duration of the study. Treatment with tPA afforded nearly 60% survival at 24 h post MIC exposure and was associated with decreased airway fibrin casts, stabilization of hypoxemia and respiratory distress, and improved acidosis. This work supports the potential of airway‐delivered tPA therapy as a useful countermeasure in stabilizing victims of high‐level MIC exposure. Our study demonstrates that airway‐delivered tPA provided partial protection against mortality, and substantially decreased airway obstruction in an acutely lethal model of MIC inhalation exposure. This approach could be useful for airway clearance in acute therapy of MIC inhalation−induced respiratory distress. Furthermore, a similar therapeutic regimen may potentially alleviate lung injuries due to other isocyanates or diisocyanates, thereby expanding its clinical importance.</description><subject>Acidosis</subject><subject>Airway management</subject><subject>airway obstruction</subject><subject>Airway Obstruction - chemically induced</subject><subject>Airway Obstruction - drug therapy</subject><subject>Airway Obstruction - physiopathology</subject><subject>Animals</subject><subject>Bhopal agent</subject><subject>Coagulation</subject><subject>Disease Models, Animal</subject><subject>Exposure</subject><subject>Fibrin</subject><subject>Hypoxemia</subject><subject>Inhalation</subject><subject>Isocyanates</subject><subject>Isocyanates - toxicity</subject><subject>Male</subject><subject>Methyl isocyanate</subject><subject>methyl isocyanate (MIC)</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Respiration</subject><subject>Respiratory failure</subject><subject>Respiratory tract</subject><subject>t-Plasminogen activator</subject><subject>Therapeutic applications</subject><subject>Tissue factor</subject><subject>tissue plasminogen activator (tPA)</subject><subject>Tissue Plasminogen Activator - pharmacology</subject><subject>Trachea</subject><issn>0077-8923</issn><issn>1749-6632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kb1uFDEQxy1ERI5AwwMgS3RIG_y1_miQThEBpIgUQEFl2d65xGF3fdjei_YNUvOIPAmbXIigYZop5je_GemP0AtKjulSb8bZlWMquBCP0IoqYRopOXuMVoQo1WjD-CF6WsoVIZRpoZ6gQ84Y58SYFfq-7nvYRVdjGnHa4AHq5dzjWFKY3egq_Lr5GcduCtBhF_O1m3HypeYp3G24scNDytX1sc7Yz7jGUibA296VIY7pAhZmQXeupvwMHWxcX-D5fT9CX0_ffTn50Jydv_94sj5rghBaNAEU9U62jnmuDWjuvedtp1WQQXPqFTEgAZjm0AYIANJI34GCTSu1o4Qfobd773byA3QBxppdb7c5Di7PNrlo_52M8dJepJ1VLTNSmUXw6l6Q048JSrVXacrj8rNlQrJWEyPZQr3eUyGnUjJsHi5QYm-DsbfB2LtgFvjl3z89oH-SWAC6B65jD_N_VPbTt_XnvfQ3sUieuA</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Nick, Heidi J.</creator><creator>Rioux, Jacqueline S.</creator><creator>Veress, Livia A.</creator><creator>Bratcher, Preston E.</creator><creator>Bloomquist, Leslie A.</creator><creator>Anantharam, Poojya</creator><creator>Croutch, Claire R.</creator><creator>Tuttle, Richard S.</creator><creator>Peters, Eric</creator><creator>Sosna, William</creator><creator>White, Carl W.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7ST</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>SOI</scope><scope>5PM</scope></search><sort><creationdate>202011</creationdate><title>Alleviation of methyl isocyanate−induced airway obstruction and mortality by tissue plasminogen activator</title><author>Nick, Heidi J. ; Rioux, Jacqueline S. ; Veress, Livia A. ; Bratcher, Preston E. ; Bloomquist, Leslie A. ; Anantharam, Poojya ; Croutch, Claire R. ; Tuttle, Richard S. ; Peters, Eric ; Sosna, William ; White, Carl W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4484-ce71ba65a2b389e83bbb35d87c6c831b709e6ee283e5cecee696bde7ef568a103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acidosis</topic><topic>Airway management</topic><topic>airway obstruction</topic><topic>Airway Obstruction - chemically induced</topic><topic>Airway Obstruction - drug therapy</topic><topic>Airway Obstruction - physiopathology</topic><topic>Animals</topic><topic>Bhopal agent</topic><topic>Coagulation</topic><topic>Disease Models, Animal</topic><topic>Exposure</topic><topic>Fibrin</topic><topic>Hypoxemia</topic><topic>Inhalation</topic><topic>Isocyanates</topic><topic>Isocyanates - toxicity</topic><topic>Male</topic><topic>Methyl isocyanate</topic><topic>methyl isocyanate (MIC)</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Respiration</topic><topic>Respiratory failure</topic><topic>Respiratory tract</topic><topic>t-Plasminogen activator</topic><topic>Therapeutic applications</topic><topic>Tissue factor</topic><topic>tissue plasminogen activator (tPA)</topic><topic>Tissue Plasminogen Activator - pharmacology</topic><topic>Trachea</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nick, Heidi J.</creatorcontrib><creatorcontrib>Rioux, Jacqueline S.</creatorcontrib><creatorcontrib>Veress, Livia A.</creatorcontrib><creatorcontrib>Bratcher, Preston E.</creatorcontrib><creatorcontrib>Bloomquist, Leslie A.</creatorcontrib><creatorcontrib>Anantharam, Poojya</creatorcontrib><creatorcontrib>Croutch, Claire R.</creatorcontrib><creatorcontrib>Tuttle, Richard S.</creatorcontrib><creatorcontrib>Peters, Eric</creatorcontrib><creatorcontrib>Sosna, William</creatorcontrib><creatorcontrib>White, Carl W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Environment Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Environment Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the New York Academy of Sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nick, Heidi J.</au><au>Rioux, Jacqueline S.</au><au>Veress, Livia A.</au><au>Bratcher, Preston E.</au><au>Bloomquist, Leslie A.</au><au>Anantharam, Poojya</au><au>Croutch, Claire R.</au><au>Tuttle, Richard S.</au><au>Peters, Eric</au><au>Sosna, William</au><au>White, Carl W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alleviation of methyl isocyanate−induced airway obstruction and mortality by tissue plasminogen activator</atitle><jtitle>Annals of the New York Academy of Sciences</jtitle><addtitle>Ann N Y Acad Sci</addtitle><date>2020-11</date><risdate>2020</risdate><volume>1479</volume><issue>1</issue><spage>134</spage><epage>147</epage><pages>134-147</pages><issn>0077-8923</issn><eissn>1749-6632</eissn><abstract>Methyl isocyanate (MIC, “Bhopal agent”) is a highly reactive, toxic industrial chemical. Inhalation of high levels (500–1000 ppm) of MIC vapor is almost uniformly fatal. No therapeutic interventions other than supportive care have been described that can delay the onset of illness or death due to MIC. Recently, we found that inhalation of MIC caused the appearance of activated tissue factor in circulation with subsequent activation of the coagulation cascade. Herein, we report that MIC exposure (500 ppm for 30 min, nose‐only) caused deposition of fibrin‐rich casts in the conducting airways resulting in respiratory failure and death within 24 h in a rat model (LC90−100). We thus investigated the effect of airway delivery of the fibrinolytic agent tissue plasminogen activator (tPA) on mortality and morbidity in this model. Intratracheal administration of tPA was initiated 11 h post MIC exposure and repeated every 4 h for the duration of the study. Treatment with tPA afforded nearly 60% survival at 24 h post MIC exposure and was associated with decreased airway fibrin casts, stabilization of hypoxemia and respiratory distress, and improved acidosis. This work supports the potential of airway‐delivered tPA therapy as a useful countermeasure in stabilizing victims of high‐level MIC exposure. Our study demonstrates that airway‐delivered tPA provided partial protection against mortality, and substantially decreased airway obstruction in an acutely lethal model of MIC inhalation exposure. This approach could be useful for airway clearance in acute therapy of MIC inhalation−induced respiratory distress. Furthermore, a similar therapeutic regimen may potentially alleviate lung injuries due to other isocyanates or diisocyanates, thereby expanding its clinical importance.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32233099</pmid><doi>10.1111/nyas.14344</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0077-8923
ispartof Annals of the New York Academy of Sciences, 2020-11, Vol.1479 (1), p.134-147
issn 0077-8923
1749-6632
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7529679
source MEDLINE; Wiley Online Library All Journals
subjects Acidosis
Airway management
airway obstruction
Airway Obstruction - chemically induced
Airway Obstruction - drug therapy
Airway Obstruction - physiopathology
Animals
Bhopal agent
Coagulation
Disease Models, Animal
Exposure
Fibrin
Hypoxemia
Inhalation
Isocyanates
Isocyanates - toxicity
Male
Methyl isocyanate
methyl isocyanate (MIC)
Morbidity
Mortality
Rats
Rats, Sprague-Dawley
Respiration
Respiratory failure
Respiratory tract
t-Plasminogen activator
Therapeutic applications
Tissue factor
tissue plasminogen activator (tPA)
Tissue Plasminogen Activator - pharmacology
Trachea
title Alleviation of methyl isocyanate−induced airway obstruction and mortality by tissue plasminogen activator
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T12%3A13%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alleviation%20of%20methyl%20isocyanate%E2%88%92induced%20airway%20obstruction%20and%20mortality%20by%20tissue%20plasminogen%20activator&rft.jtitle=Annals%20of%20the%20New%20York%20Academy%20of%20Sciences&rft.au=Nick,%20Heidi%20J.&rft.date=2020-11&rft.volume=1479&rft.issue=1&rft.spage=134&rft.epage=147&rft.pages=134-147&rft.issn=0077-8923&rft.eissn=1749-6632&rft_id=info:doi/10.1111/nyas.14344&rft_dat=%3Cproquest_pubme%3E2462580962%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2462580962&rft_id=info:pmid/32233099&rfr_iscdi=true